Odonate Announces Expected Delisting of Its Stock
2022年1月7日 - 11:00PM
ビジネスワイヤ(英語)
Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on
January 6, 2022 it received written notice from The Nasdaq Stock
Market LLC (“Nasdaq”) notifying Odonate that Nasdaq believes that
Odonate is a "public shell" pursuant to Listing Rule 5101, and that
the continued listing of its securities is no longer warranted.
Odonate will not appeal this determination. Therefore, Odonate
expects the trading of its common stock on The Nasdaq Stock Market
to be suspended at the opening of business on January 18, 2022, and
that Nasdaq will file a Form 25-NSE with the U.S. Securities and
Exchange Commission (the “SEC”), which will remove Odonate’s
securities from listing and registration on The Nasdaq Stock
Market. Additionally, Odonate intends to file with the SEC a Form
15 requesting the suspension of the Company’s reporting
obligations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220107005100/en/
Odonate Therapeutics, Inc. Michael Hearne Chief Financial
Officer (332) 208-7611 mhearne@odonate.com
Odonate Therapeutics (NASDAQ:ODT)
過去 株価チャート
から 5 2024 まで 6 2024
Odonate Therapeutics (NASDAQ:ODT)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Odonate Therapeutics Inc (ナスダック市場): 0 recent articles
その他のOdonate Therapeutics, Inc.ニュース記事